Research

LIke ThisLIke ThisLIke This

Ahmet Uluer, Do

Uluer Ahmet MD
Department:
Medicine Research
Division
Respiratory Diseases Research
Hospital Title:
Director, Adult Cystic Fibrosis Program; Director, Weitzman Family Bridges Adult Transition Program
Academic Title:
Assistant Professor of Pediatrics, Harvard Medical School
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Publications

Publications powered by Harvard Catalyst Profiles
  1. Wilschanski M, Yaakov Y, Omari I, Zaman M, Martin CR, Cohen-Cymberknoh M, Shoseyov D, Kerem E, Dasilva D, Sheth S, Uluer A, O'Sullivan BP, Freedman S. Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function. J Pediatr Gastroenterol Nutr. 2016 Nov; 63(5):e92-e97.
  2. Putman MS, Greenblatt LB, Sicilian L, Uluer A, Lapey A, Sawicki G, Gordon CM, Bouxsein ML, Finkelstein JS. Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Osteoporos Int. 2016 Aug; 27(8):2497-505.
  3. Tarshish Y, Huang L, Jackson FI, Edwards J, Fligor B, Wilkins A, Uluer A, Sawicki G, Kenna M. Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. J Am Acad Audiol. 2016 Jan; 27(1):6-12.
  4. Nie S, Zhang H, Mayer KM, Oppenheim FG, Little FF, Greenberg J, Uluer AZ, Walt DR. Correlations of salivary biomarkers with clinical assessments in patients with cystic fibrosis. PLoS One. 2015; 10(8):e0135237.
  5. Nie S, Henley WH, Miller SE, Zhang H, Mayer KM, Dennis PJ, Oblath EA, Alarie JP, Wu Y, Oppenheim FG, Little FF, Uluer AZ, Wang P, Ramsey JM, Walt DR. An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples. Lab Chip. 2014 Mar 21; 14(6):1087-98.
  6. Uluer AZ, Waltz DA, Kalish LA, Adams S, Gerard C, Ericson DA. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. J Cyst Fibros. 2013 Jan; 12(1):54-9.
  7. Demars N, Uluer A, Sawicki GS. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil. 2011; 33(11):922-6.
  8. Cheng AG, Johnston PR, Luz J, Uluer A, Fligor B, Licameli GR, Kenna MA, Jones DT. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 2009 Jul; 141(1):86-90.
  9. Spilker T, Uluer AZ, Marty FM, Yeh WW, Levison JH, Vandamme P, Lipuma JJ. Recovery of Herbaspirillum species from persons with cystic fibrosis. J Clin Microbiol. 2008 Aug; 46(8):2774-7.
  10. Campodónico VL, Gadjeva M, Paradis-Bleau C, Uluer A, Pier GB. Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends Mol Med. 2008 Mar; 14(3):120-33.
  11. Show all
  12. Wood GS, Uluer AZ. Polymerase chain reaction/denaturing gradient gel electrophoresis (PCR/DGGE): sensitivity, band pattern analysis, and methodologic optimization. Am J Dermatopathol. 1999 Dec; 21(6):547-51.
  13. Roth BL, Choudhary MS, Khan N, Uluer AZ. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther. 1997 Feb; 280(2):576-83.
  14. Wood GS, Crooks CF, Uluer AZ. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol. 1995 Jul; 105(1):51-5.
  15. Choudhary MS, Sachs N, Uluer A, Glennon RA, Westkaemper RB, Roth BL. Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. Mol Pharmacol. 1995 Mar; 47(3):450-7.
  16. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar; 268(3):1403-10.
  17. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18; 363(21):1991-2003.
  18. Roth BL, Palvimaki EP, Berry S, Khan N, Sachs N, Uluer A, Choudhary MS. 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther. 1995 Dec; 275(3):1638-46.
  19. Legere HJ, Palis RI, Rodriguez Bouza T, Uluer AZ, Castells MC. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros. 2009 Dec; 8(6):418-24.
  20. Putman MS, Milliren CE, Derrico N, Uluer A, Sicilian L, Lapey A, Sawicki G, Gordon CM, Bouxsein ML, Finkelstein JS. Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab. 2014 Sep; 99(9):3399-407.
  21. Putman MS, Baker JF, Uluer A, Herlyn K, Lapey A, Sicilian L, Tillotson AP, Gordon CM, Merkel PA, Finkelstein JS. Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. J Cyst Fibros. 2015 Jul; 14(4):526-32.
LIke ThisLIke ThisLIke This
Close